Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Nutraplus India's share price for the quarter that ended in Mar. 2026 was ₹2.1. Nutraplus India's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 34.09 Mil. Therefore, Nutraplus India's market cap for the quarter that ended in Mar. 2026 was ₹71.59 Mil.
Nutraplus India's quarterly market cap
stayed the same
from Sep. 2025 (₹0.00 Mil) to Dec. 2025 (₹0.00 Mil) but then
increased
from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹71.59 Mil).
Nutraplus India's annual market cap
declined
from Mar. 2024 (₹71.59 Mil) to Mar. 2025 (₹0.00 Mil) but then
increased
from Mar. 2025 (₹0.00 Mil) to Mar. 2026 (₹71.59 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Nutraplus India's Enterprise Value for Today is ₹827.51 Mil.
Nutraplus India (BOM:524764) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Nutraplus India Market Cap Related Terms
Nutraplus India Market Cap Historical Data
* Premium members only.
The historical data trend for Nutraplus India's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nutraplus India's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nutraplus India Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nutraplus India's Market Cap distribution charts can be found below:
* The bar in red indicates where Nutraplus India's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Nutraplus India's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutraplus India (BOM:524764) has a Market Cap of ₹71.59 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nutraplus India and its competitors.
Is Nutraplus India's Market Cap too high?
Nutraplus India's current Market Cap is ₹71.59 Mil.
How does Nutraplus India's Market Cap compare to ZTS?
Nutraplus India's Market Cap of ₹71.59 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 213.52. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 213.52, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Nutraplus India and its competitors. For the Drug Manufacturers industry, the median Market Cap is 213.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nutraplus India's current Market Cap is ₹71.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nutraplus India stock overvalued right now?
Nutraplus India (BOM:524764) has a current Market Cap of ₹71.59 Mil. The current Market Cap is ₹71.59 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Nutraplus India (BOM:524764), the current Market Cap is ₹71.59 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nutraplus India Ltd is an India based company engaged in manufacturing of active pharmaceutical ingredients (API), intermediates and contract manufacturing of intermediates. It produces bulk drugs, and specialty chemicals and intermediates. The company's product portfolio encompasses therapeutic categories like analgesic, anti-asthma, antimalarial, anti-protozoan infections, mucolyting agent, and antihelmintic.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524764 has been successfully added to your 